scholarly journals Enhanced Tumor Cell Isolation by a Biomimetic Combination of E-selectin and anti-EpCAM: Implications for the Effective Separation of Circulating Tumor Cells (CTCs)

Langmuir ◽  
2010 ◽  
Vol 26 (11) ◽  
pp. 8589-8596 ◽  
Author(s):  
Ja Hye Myung ◽  
Cari A. Launiere ◽  
David T. Eddington ◽  
Seungpyo Hong
Keyword(s):  
Tumor Cell ◽  
Tumor Cells ◽  
Circulating Tumor Cells ◽  
Cell Isolation ◽  
Effective Separation

Isolation of Circulating Tumor Cells Using Stiffness-Based Filtration Platform

2015 ◽  
Author(s):  
Emrah Celik ◽  
Nicolas Rongione ◽  
Amelia Bahamonde ◽  
Zheng Ao ◽  
Ram Datar
Keyword(s):  
Tumor Cell ◽  
Cancer Cells ◽  
Tumor Cells ◽  
Circulating Tumor Cells ◽  
Blood Cells ◽  
High Efficiency ◽  
White Blood Cells ◽  
Cell Isolation ◽  
Element Analysis ◽  
Cancer Disease

Analysis of isolated cancer cells in circulation is proven to help determine the success of the cancer treatment and understand the genetic signature of cancer disease. Scarcity of these cells in blood circulation (1–10 CTC in 1ml blood) however, makes the isolation process extremely challenging. Ever improving CTC isolation methods fall into two main categories: 1.Immunomagnetic separation based on antibody binding to tumor specific biomarkers expressed on the cell 2. Physical separation based on the size of the CTCs. Efficiency in cell isolation is still low in these techniques due to the variation in expression level of tumor specific antigens and tumor cell size. Therefore, tumor cell isolation strategies using new CTC biomarkers must be explored. In this study, we investigated the feasibility of using mechanical stiffness difference in order to detect and isolate the circulating tumor cells from the blood cells. AFM nanindentation experiments revealed that cancer cells are significantly softer than the surrounding white blood cells and therefore, stiffness can be used as a biomarker for CTC isolation. In addition, finite element analysis simulations have shown that CTC isolation can be performed at high efficiency using stiffness-based isolation. Therefore, stiffness based isolation has a potential to achieve fast, label-free isolation of CTCs at high efficiency for clinical applications.

Circulating tumor cell detection using a parallel flow micro-aperture chip system

Lab on a Chip ◽  
2015 ◽  
Vol 15 (7) ◽  
pp. 1677-1688 ◽  
Author(s):  
Chun-Li Chang ◽  
Wanfeng Huang ◽  
Shadia I. Jalal ◽  
Bin-Da Chan ◽  
Aamer Mahmood ◽  
...  
Keyword(s):  
Tumor Cell ◽  
Tumor Cells ◽  
Circulating Tumor Cells ◽  
Circulating Tumor Cell ◽  
Parallel Flow ◽  
Cell Detection ◽  
Tumor Cell Detection ◽  
System P

A parallel flow micro-aperture chip system for detection of circulating tumor cells.

scholarly journals Microfluidics-enabled rapid manufacturing of hierarchical silica-magnetic microflower toward enhanced circulating tumor cell screening

2018 ◽  
Vol 6 (12) ◽  
pp. 3121-3125 ◽  
Author(s):  
Nanjing Hao ◽  
Yuan Nie ◽  
Amogha Tadimety ◽  
Ting Shen ◽  
John X. J. Zhang
Keyword(s):  
Tumor Cell ◽  
Tumor Cells ◽  
Circulating Tumor Cells ◽  
Circulating Tumor Cell ◽  
Rapid Manufacturing ◽  
Screening Efficiency

Microfluidics-enabled rapid manufacturing of a hierarchical silica-magnetic microflower was developed for improving the screening efficiency of circulating tumor cells.

Serum HER2 in the context of circulating tumor cells in patients with metastatic breast cancer.

2012 ◽  
Vol 30 (15_suppl) ◽  
pp. 10599-10599 ◽  
Author(s):  
Volkmar Mueller ◽  
Sabine Riethdorf ◽  
Brigitte Kathrin Rack ◽  
Wolfgang Janni ◽  
Peter A. Fasching ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Tumor Cell ◽  
Tumor Cells ◽  
Circulating Tumor Cells ◽  
Elevated Serum ◽  
Metastatic Breast ◽  
Serum Levels ◽  
Her2 Status ◽  
Cellsearch System ◽  
Prognostic Information

10599 Background: Circulating tumor cells (CTC) reflect an aggressive tumor behavior by hematogenous tumor cell dissemination. Overexpression of HER2 in breast cancer (BC) is associated with increased angiogenesis and therefore potentially linked to increased hematogenous tumor cell spread. The aim of the analysis was to investigate whether concentrations of serum HER2 (sHER2) deliver prognostic information in the context of CTC detection in metastatic BC patients. Methods: Blood was obtained in a prospective multicenter setting from 254 patients with metastatic BC at the time of disease progression. sHER2 was determined using a commercial ELISA-kit (Wilex). CTC were detected with the CellSearch system (Veridex). Patients received systemic treatment according to national and international guidelines including HER2-targeted treatment. Results: Five or more CTC were detected in 122 of 245 evaluable patients (49.8%).119 of 251 (47%) metastatic patients had serum sHER2 levels above 15ng/mL. Median PFS was 9.2 months (95%-CI: 9.9 – 13.0 mths) with elevated sHER2 versus 11.4 mths (9.9 – 13.0 mths) with non-elevated levels (p=0.07). OS was 17.4 mths (14.6 – 20.3 mths) vs. 26.5 mths (23.1-29.8 mths; p<0.01). In patients with 5 or more CTC, serum levels were above the cut-off for sHER2 in 61% vs. 33% in those with less than 5 CTC (p< 0.01). Patients with elevated sHER and 5 or more CTC hat a PFS of 9.1 mths (7.2 – 11.1 mths) and a OS of 14.5 mths (11.8 – 17.2 mths), those with non-elevated sHER2 and less than 5 CTC a PFS of 12.1 (10.1 – 14.1 mths) and a OS of 29.5 month (25.4 – 33.6 mths) (p=0.15 for PFS and p< 0.01 for OS). Including sHER2, CTC and established prognostic factors in the multivariate analysis, the presence of CTC, line of therapy, ER and HER2 status of the primary tumor remained independent predictors of OS. Conclusions: Elevated serum levels of sHER2 are associated with the presence of CTC and indicate poor clinical outcome. However, sHER2 has no independent prognostic value when presence of CTC were taken into account.

Sign in / Sign up

Export Citation Format

Share Document